Blue Matter buys London's Cognite to scale biopharma communications
What's the deal? Blue Matter, a strategic consulting firm serving the life sciences industry, has acquired Cognite, a London-based global healthcare communications agency. Financial terms were not disclosed.
What each side brings: Blue Matter, headquartered in San Francisco, advises pharmaceutical and biotech companies on corporate, portfolio, and product strategy. Cognite — with offices in London, Zug, and Boston — specialises in scientific, medical, corporate, and patient communications, focusing on complex specialty markets including rare diseases.
The rationale: Blue Matter has spent recent years building the creative and communications capabilities needed to execute its strategy work. "Cognite's array of capabilities, creativity, and team culture are a perfect fit for the Blue Matter family," said chief executive officer Ashwin Dandekar.
Why now? The deal advances a stated growth plan. After backer Baird CapitalDealroom has a profile for this one. Try Dealroom → closed an oversubscribed continuation fund in May to fuel the business, Blue Matter said it would scale medical and market-access communications and pursue add-on acquisitions.
What's the endgame? The acquisition extends Blue Matter's offer from strategy toward execution, pairing two founder-led businesses. "By becoming part of Blue Matter, we will be able to take our communications skills and experience to a far wider audience," said Cognite chief executive officer Lee Hurley.
Baird reported roughly 25% organic annual growth at Blue Matter since its 2020 investment. Reed SmithDealroom has a profile for this one. Try Dealroom → advised Blue Matter; Rothschild CoDealroom has a profile for this one. Try Dealroom → and DLA PiperDealroom has a profile for this one. Try Dealroom → advised Cognite.
The signal: The deal fits a broader push to combine life-sciences strategy consulting with scientific and medical communications. In June, Klick Health bought Oxford PharmaGenesisDealroom has a profile for this one. Try Dealroom → to broaden its medical-affairs and market-access capabilities, while Envision Pharma GroupDealroom has a profile for this one. Try Dealroom →'s October purchase of 90TENDealroom has a profile for this one. Try Dealroom → added behavioural-science and communications expertise. With terms undisclosed, the deal's scale cannot be assessed.
Read more: finanznachrichten.de
Image credit: Generated with Gemini
